Behavior of the anti-apoptotic BCL-2 protein in non-small-cell lung cancer cell models in response to treatments with ALK inhibitors and its potential dual BCL2ALK inhibition
DOI:
https://doi.org/10.24265/horizmed.2024.v24n3.12Keywords:
Small Molecule Libraries, Carcinoma, Non-Small-Cell Lung, Inhibitors, Tyrosine Kinase, Proto-Oncogene Proteins c-bcl-2, Anaplastic Lymphoma Kinase, Molecular Docking SimulationAbstract
Objective: To describe the behavior of the BCL-2 protein in non-small-cell lung cancer cell models in response to treatment with ALK (anaplastic lymphoma kinase) protein tyrosine kinase inhibitors (crizotinib and alectinib) and their potential dual BCL-2-ALK inhibition. Materials and methods: Three non-small-cell-lung cancer cell models were used: Ba/f3 EML4-ALKWT, Ba/f3 EML4-ALKL1196M and Ba/f3 EML4-ALKG1202R, generated by site-directed mutagenesis. These were treated with crizotinib and alectinib in a dose-responsive manner, and an apoptosis assay was also conducted to confirm pharmacological susceptibility. Subsequently, BCL-2 protein expression was measured under three treatment conditions (no treatment, 100 nM crizotinib and 50 nM alectinib). Finally, a search for BCL-2 and ALK ligands was performed for molecular docking simulation and interaction energy calculation, measured in kcal/mol in the YASARA™ program. Results: The WT model evidenced sensitivity to crizotinib and alectinib, with apoptosis percentages of 23 % and 74 %, respectively; G1202R showed resistance to both drugs (apoptosis: 5 %), and L1196M resistance to crizotinib (apoptosis: 12 %) and sensitivity to alectinib (apoptosis: 25 %). BCL-2 expression revealed overexpression in the WT and G1202R models, while L1196M showed expression close to baseline. Finally, bioinformatics findings identified ABT-199 (which is part of small molecule libraries) as the best candidate to inhibit BCL-2, while its interaction with ALKL1196M revealed interaction energies higher than those obtained in the interaction with crizotinib and alectinib. Conclusions: The cell models exhibited the pharmacological susceptibility described in the literature, BCL-2 expression during treatments remained overexpressed in WT and G1202R, while L1196M showed no variation. Finally, bioinformatics f indings suggest ABT-199 as a potential dual action inhibitor due to its higher interaction energy with ALK.
Downloads
References
American Society of Clinical Oncology. Lung Cancer - Non-Small Cell: Statistics [Internet]. Estados Unidos: ASCO; 2023. Disponible en : https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/ statistics
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin [Internet]. 2023;73(1):17-48
Chevallier M, Borgeaud M, Addeo A, Friedlaender A. Oncogenic driver mutations in non-small cell lung cancer: past, present and future. World J Clin Oncol [Internet]. 2021;12(4):217-37.
Stella GM, Luisetti M, Pozzi E, Comoglio PM. Oncogenes in nonsmall-cell lung cancer: Emerging connections and novel therapeutic dynamics. Lancet Respir Med [Internet]. 2013;1(3):251-61.
Du X, Shao Y, Qin H-F, Tai Y-H, Gao H-J, Yan-Hong Tai C. ALKrearrangement in non-small-cell lung cancer(NSCLC) . Thorac Cancer [Internet]. 2018;9:423-30.
Hallberg B, Palmer RH. The role of the ALK receptor in cancer biology. Ann Oncol [Internet]. 2016;27(3):iii4-iii15
Arbour KC, Riely GJ. Diagnosis and treatment of anaplastic lymphoma kinase–positive non–small cell lung cancer. Hematol Oncol Clin North Am [Internet]. 2017;31(1):101-11.
Liao BC, Lin CC, Shih JY, Yang JCH. Treating patients with ALKpositive non-small cell lung cancer: latest evidence and management strategy. Ther Adv Med Oncol [Internet]. 2015;7(5):274-90
Pan Y, Deng C, Qiu Z, Cao C, Wu F. The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer. Front Oncol [Internet]. 2021;11:1-13.
Wang YW, Tu PH, Lin KT, Lin SC, Ko JY, Jou YS. Identification of oncogenic point mutations and hyperphosphorylation of anaplastic lymphoma kinase in lung cancer. Neoplasia [Internet]. 2011;13(8):704-15.
Hafezi S, Rahmani M. Targeting bcl-2 in cancer: Advances, challenges, and perspectives. Cancers (Basel) [Internet]. 2021;13(6):1-13.
Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell [Internet]. 2011;144(5):646-74.
Cang S, Iragavarapu C, Savooji J, Song Y, Liu D. ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. J Hematol Oncol [Internet]. 2015;8(1):1-8.
Muenchow A, Weller S, Hinterleitner C, Malenke E, Bugl S, Wirths S, et al. The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA. Cell Death Dis [Internet]. 2020;11(8):701.
Instituto Nacional del Cáncer. Terapia de combinación con venetoclax aprobada para LLC - NCI [Internet]. Estados Unidos: NIH; 2019. Disponible en: https://www.cancer.gov/espanol/noticias/temas-yrelatos-blog/2019/venetoclax-obinutuzumab-fda-aprobacion-llc-llp
Fontana D, Ceccon M, Gambacorti-Passerini C, Mologni L. Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK. Cancer Med [Internet]. 2015;4(7):953-65.
Krieger E, Vriend G. YASARA View - molecular graphics for all devices - from smartphones to workstations. Bioinformatics [Internet]. 2014;30(20):2981-2.
Huang F, Greer A, Hurlburt W, Han X, Hafezi R, Wittenberg GM, et al. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res [Internet]. 2009;69(1):161-70.
UniProt. BCL2 - Apoptosis regulator Bcl-2 - Homo sapiens (Human) [Internet]. Suiza: UniProt; 2017. Disponible en: https://www. uniprot.org/uniprotkb/A0A1L4AQQ5/entry
Birkinshaw RW, Gong J nan, Luo CS, Lio D, White CA, Anderson MA, et al. Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations. Nat Commun [Internet]. 2019;10(1):2385.
UniProt. ALK - ALK tyrosine kinase receptor - Homo sapiens (Human) [Internet]. Suiza: UniProt; 2010. Disponible en: https://www. uniprot.org/uniprotkb/Q9UM73/entry
Huang Q, Johnson TW, Bailey S, Brooun A, Bunker KD, Burke BJ, et al. Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib. J Med Chem [Internet]. 2014;57(4):1170-187.
Sakamoto H, Tsukaguchi T, Hiroshima S, Kodama T, Kobayashi T, Fukami TA, et al. CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant. Cancer Cell [Internet]. 2011;19(5):679-90.
Bayliss R, Choi J, Fennell DA, Fry AM, Richards MW. Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs. Cell Mol Life Sci [Internet]. 2016;73(6):120-24.
Elshatlawy M, Sampson J, Clarke K, Bayliss R. EML4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries. Mol Oncol [Internet]. 2023;17(6):950-63.
Anagnostou VK, Lowery FJ, Zolota V, Tzelepi V, Gopinath A, Liceaga C, et al. High expression of BCL-2 predicts favorable outcome in nonsmall cell lung cancer patients with non squamous histology. BMC Cancer [Internet]. 2010;10(1):1-11.
Zhang J, Wang S, Wang L, Wang R, Chen S, Pan B, et al. Prognostic value of Bcl-2 expression in patients with non-small-cell lung cancer: a meta-analysis and systemic review. Onco Targets Ther [Internet]. 2015;8:3361-9.
Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov [Internet]. 2022;12(1):31-46.
Vogler M. Targeting BCL2-Proteins for the Treatment of Solid Tumours. Adv Med [Internet]. 2014;2014:1-14.
Shi Y, Ye J, Yang Y, Zhao Y, Shen H, Ye X, et al. The Basic Research of the Combinatorial Therapy of ABT-199 and Homoharringtonine on Acute Myeloid Leukemia. Front Oncol [Internet]. 2021;11:1-10.
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Horizonte Médico (Lima)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Horizonte Médico (Lima) (Horiz. Med.) journal’s research outputs are published free of charge and are freely available to download under the open access model, aimed at disseminating works and experiences developed in biomedical and public health areas, both nationally and internationally, and promoting research in the different fields of human medicine. All manuscripts accepted and published in the journal are distributed free of charge under the terms of a Creative Commons license – Attribution 4.0 International (CC BY 4.0).
